|Videos|December 21, 2020

The Case for Pooled SARS-CoV-2 Testing

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

A new study from the Duke University School of Medicine showed pooled testing, rather than individual testing, can extend SARS-CoV-2 test supplies and increase the number of patients tested and cases detected.

Such benefits could indicate a better utility of such assays for population screening and resource-constrained settings, according to the teams findings published in JAMA Network Open.

Though such measures—as observed by Christopher Polage, MD, of the Duke Health System Clinical Laboratories, and colleagues—may mean a convoluted workflow, lower sensitivity in some test cases, and the potential need for repeat tests in the event of positive pools, the team suggested sequential two-stage pooling could at least reduce the burden of retesting from positive large pools.

The team’s evidenced findings comparing the methods could even offer policy makers informed guidance for regional and national decision-making on how the pandemic is better tested and monitored in 2021.

In an interview with Contagion, Polage discussed discussed the team’s interest in informing both public health and clinical institutions which could possibly benefit from pooled testing, as well as the unfortunately ill-established models of theoretical-based pooled testing currently underway.

“We’ve seen a few publications and commentaries that have suggested the possible value and benefit of pooled testing, but we haven’t actually seen a lot of pooled testing use in actual practices, universities and surveillance programs,” Polage explained.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.